179 related articles for article (PubMed ID: 11679925)
1. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
McFarland EJ; Borkowsky W; Fenton T; Wara D; McNamara J; Samson P; Kang M; Mofenson L; Cunningham C; Duliege AM; Sinangil F; Spector SA; Jimenez E; Bryson Y; Burchett S; Frenkel LM; Yogev R; Gigliotti F; Luzuriaga K; Livingston RA;
J Infect Dis; 2001 Nov; 184(10):1331-5. PubMed ID: 11679925
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
Borkowsky W; Wara D; Fenton T; McNamara J; Kang M; Mofenson L; McFarland E; Cunningham C; Duliege AM; Francis D; Bryson Y; Burchett S; Spector SA; Frenkel LM; Starr S; Van Dyke R; Jimenez E
J Infect Dis; 2000 Mar; 181(3):890-6. PubMed ID: 10720509
[TBL] [Abstract][Full Text] [Related]
3. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.
Cunningham CK; Wara DW; Kang M; Fenton T; Hawkins E; McNamara J; Mofenson L; Duliege AM; Francis D; McFarland EJ; Borkowsky W;
Clin Infect Dis; 2001 Mar; 32(5):801-7. PubMed ID: 11229849
[TBL] [Abstract][Full Text] [Related]
4. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.
Pitisuttithum P; Nitayaphan S; Thongcharoen P; Khamboonruang C; Kim J; de Souza M; Chuenchitra T; Garner RP; Thapinta D; Polonis V; Ratto-Kim S; Chanbancherd P; Chiu J; Birx DL; Duliege AM; McNeil JG; Brown AE;
J Infect Dis; 2003 Jul; 188(2):219-27. PubMed ID: 12854076
[TBL] [Abstract][Full Text] [Related]
8. Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women.
Wright PF; Lambert JS; Gorse GJ; Hsieh RH; McElrath MJ; Weinhold K; Wara DW; Anderson EL; Keefer MC; Jackson S; Wagner LJ; Francis DP; Fast PE; McNamara J
J Infect Dis; 1999 Oct; 180(4):1080-8. PubMed ID: 10479134
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
Johnson DC; McFarland EJ; Muresan P; Fenton T; McNamara J; Read JS; Hawkins E; Bouquin PL; Estep SG; Tomaras GD; Vincent CA; Rathore M; Melvin AJ; Gurunathan S; Lambert J
J Infect Dis; 2005 Dec; 192(12):2129-33. PubMed ID: 16288378
[TBL] [Abstract][Full Text] [Related]
11. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
Gilbert PB; Peterson ML; Follmann D; Hudgens MG; Francis DP; Gurwith M; Heyward WL; Jobes DV; Popovic V; Self SG; Sinangil F; Burke D; Berman PW
J Infect Dis; 2005 Mar; 191(5):666-77. PubMed ID: 15688279
[TBL] [Abstract][Full Text] [Related]
12. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G
Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Flynn NM; Forthal DN; Harro CD; Judson FN; Mayer KH; Para MF;
J Infect Dis; 2005 Mar; 191(5):654-65. PubMed ID: 15688278
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
[TBL] [Abstract][Full Text] [Related]
16. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
[TBL] [Abstract][Full Text] [Related]
18. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
20. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
